The present invention provides a crystal of a pharmaceutically acceptable salt of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl- -3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, and has characteristics suitable for applications of oral pharmaceutical preparations.

Kirin Beer Kabushiki Kaisha

N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxaz- olyl)urea salt in crystalline form

Methods are disclosed to treat viral infections, particularly hepatitis C, herpes simplex, Kaposi's sarcoma and HIV, comprising administrating a (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative or (5-aryl-1,2,4-thiadiazol)-3-yl urea derivative of the formula: ##STR1##wherein X is oxygen or sulfur, R is hydrogen or alkyl having from 1-3 carbons, n is 0-4, R.sub.1 is independently selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo or fluoro, oxychloro, alkoxy having the formula --O(CH.sub.2).sub.y CH.sub.3 wherein y is from 1 to 6, or a pharmaceutically acceptable acid addition salt or prodrug thereof. The preferred compound is (5-phenyl-1,2,4-thiadazol-3-yl) thiourea.

The Procter &amp; Gamble Company

Viral treatment

Herein described is an invention of the usage, design and effective procedures 1.) for selected combined methods for preparation and 2.) for coordination of sequence, dosage and administration in utilizing anti-HIV thiophenoyl urea TUR (or related drugs) chemotherapy as well as for utilizing HIV induced or augmented nonvirion antigen NVA (or early polypeptide vaccine EPV or related or derivative) immunotherapy in treatment of HIV+ and AIDS patients (and applicable to Karposi's sarcoma and to other retroviral diseases). Herein described is an invention of 3.) the usage, design and effective procedures for a combination of TUR and NVA (or similar elements) as specific active immunochemotherapy for the treatment of HIV positive and AIDS patients, which consists of a vaccine (NVA) composed of separated and concentrated early virus-induced or augmented nonvirion polypeptides which induce long-lasting cell-mediated immunity administered at the peak of effects by a synergistic antiviral drug, TUR, which causes minimal or no resistance.

urea/sarcoma

N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxaz- olyl)urea salt in crystalline form

Viral treatment

Anti-HIV /Aids Chemo(C)-, immuno(I)-, or ci-therapy using tur (or related compounds) and/or NVA (or EPV)

科学に裏打ちされた最も完全な薬草データベース